• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    COMPASS Pathways (CMPS) Is Getting Fresh Attention, What Is The Market Weighing?

    Simply Wall St·11/12/2026 06:20:46
    Listen to the news

    COMPASS Pathways (NasdaqGS:CMPS) just hit a key milestone, completing its New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression. The news puts regulatory risk and timelines in sharper focus for investors.

    Investors have already been repositioning around COMPASS Pathways, with the 7 day share price return of 19.1% partly reversing a 30 day decline of 16.5% and a 90 day drop of 30.9%. At the same time, the year to date share price gain of 42% and 1 year total shareholder return of 75.8% point to strong but volatile momentum building around the NDA and recent earnings progress.

    Capitalize on the momentum around COMPASS Pathways by scanning a hand picked 19 high quality undiscovered gems that also focus on breakthrough therapies and strong underlying fundamentals.

    For COMPASS Pathways, the question is whether this sharp swing reflects improving fundamentals around COMP360 and recent losses, or whether sentiment has simply run ahead of where the valuation now sits.

    Most Popular Narrative: 62% Undervalued

    Against a last close of $9.30, the analyst consensus Narrative on Simply Wall St anchors COMPASS Pathways at a fair value of $24.47, implying a wide gap that analysts tie directly to the COMP360 program and its potential earnings power.

    COMPASS Pathways currently has no revenue. Analysts are forecasting revenue to reach $284.9 million by July 2029.

    Analysts are not forecasting that COMPASS Pathways will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate COMPASS Pathways's profit margin will increase from 0.0% to the average US Biotechs industry of 18.9% in 3 years.

    See why 15 investors see COMPASS Pathways as 62% undervalued.

    The fair value in that Narrative is built using a 7.63% discount rate and a long term earnings profile that assumes COMP360 eventually reaches a profit margin close to the wider US Biotechs sector. That framework also bakes in a future P/E of 93.4x on the 2029 earnings estimate of $53.9 million, which is much higher than the 17.6x multiple used for the broader industry in the same analysis.

    None of these figures are forecasts in themselves, they are the conditions that would need to hold for the $24.47 price target to line up with today’s $9.30 market price. For readers, the key task is to decide whether a very large revenue ramp from $0, combined with that kind of earnings multiple, feels reasonable given COMPASS Pathways’ Phase III and NDA path for COMP360.

    Result: Fair Value of $24.47 (UNDERVALUED)

    Still, the narrative around COMPASS Pathways hinges on successful Phase III outcomes and FDA approval, while high cash usage increases the chance of future shareholder dilution.

    Find out about the key risks to this COMPASS Pathways narrative.

    Next Steps

    If the COMPASS Pathways story feels finely balanced between risk and reward, that is exactly the point. This is why you should pressure test the numbers and assumptions yourself, then weigh the 2 key rewards and 4 important warning signs.

    Looking for more investment ideas beyond COMPASS Pathways?

    Do not stop your research with COMPASS Pathways. Broaden your watchlist with other potential opportunities that match the kind of risk and reward profile you care about most.